Table S2 from First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J. Sullivan, Jeffrey R. Infante,Filip Janku,Deborah Jean Lee Wong,Jeffrey A. Sosman,Vicki Keedy,Manish R. Patel,Geoffrey I. Shapiro,James W. Mier,Anthony W. Tolcher,Andrea Wang-Gillam,Mario Sznol,Keith Flaherty,Elizabeth Buchbinder,Richard D. Carvajal, Anna M. Varghese,Mario E. Lacouture,Antoni Ribas, Sapna P. Patel,Gary A. DeCrescenzo,Caroline M. Emery,Anna L. Groover,Saurabh Saha,Mary Varterasian,Dean J. Welsch,David M. Hyman, Bob T. Liopenalex（2023）引用 0|浏览0关键词Treatment DiscontinuationAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
